Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
PhIb, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and PK of an i.v. mAb After Single Ascending Doses in Subjects Affected by Idiopathic Pulmonary Fibrosis.
Verified date | April 2024 |
Source | Chiesi Farmaceutici S.p.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety of CHF10067 (the study drug) and any side effects that might be associated with it. In addition, the study will evaluate how much of the study drug gets into the bloodstream and how long the body takes to remove it. The body's immune response to the study drug will also be evaluated. The study may also evaluate the effect of the study drug on the level of a certain protein in the body. Chiesi is conducting this study on patients affected by idiopathic pulmonary fibrosis (IPF, a lung disease). Chiesi is doing this study to establish the doses suitable for future studies.
Status | Active, not recruiting |
Enrollment | 24 |
Est. completion date | June 25, 2024 |
Est. primary completion date | June 25, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - Subject's written informed consent obtained prior to any study-related procedure. - Males or females, of any race, aged = 40 years of age. - Body weight = 45 kg. - Diagnosis of IPF as defined by current American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines. Diagnosis of IPF must be within the past 5 years prior to enrolment, and in the opinion of the Investigator, has been stable for at least 3 months. - Subjects not receiving any IPF treatment (including subjects with previous use of antifibrotic treatment that has been stopped for at least 2 weeks prior to screening) or receiving well-tolerated standard of care approved treatments at a stable dose for at least 8 weeks prior to screening (nintedanib or pirfenidone) and it is anticipated the dose will remain unchanged throughout the study. - Forced vital capacity (FVC) = 50% of predicted and ratio of forced expiratory volume in the first second (FEV1)/FVC = 0.7 at screening. - Diffusing capacity of the lung for carbon monoxide (DLCO; corrected for haemoglobin) = 35% at screening. - Able to understand the study procedures and the risks involved. - Male and Female subjects following contraceptive requirements detailed in the study protocol. Exclusion Criteria: - History of lower respiratory tract infection within 4 weeks prior to screening and up to Day 1 of the study. - History of acute exacerbation of IPF within 3 months prior to screening and up to Day 1 of the study - Active diagnosis of lung cancer or a history of lung cancer. - Active cancer or a history of cancer (other than lung cancer) with less than 5 years disease free survival time (whether or not there is evidence of local recurrence or metastases). - Infiltrative lung disease other than IPF - Subjects exhibiting unhealed wounds or foot ulcers or have known history of wound healing complications. - Chronic heart failure categorized as New York Heart Association Class II, III, or IV; clinical diagnosis of cor pulmonale requiring specific treatment; or severe pulmonary hypertension - Currently receiving, or have received, a systemic corticosteroid, immunosuppressant, cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved or investigational treatment for IPF within 4 weeks prior to screening or prior to randomization. - Coronavirus disease-2019 (COVID-19) vaccine at least 7 days before dosing. Any systemic symptoms (e.g. myalgia, fever, chills, fatigue, etc.) after COVID-19 vaccine should subside at least 2 days before the Day 1 visit. - Documented COVID-19 diagnosis within the last 4 weeks or which has not resolved within 7 days prior to screening or before treatment. - Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation or any other substance used in the study. - History of allergic or anaphylactic reaction to human, humanised, chimeric, immunoglobulins (Igs), or murine monoclonal antibodies. - Clinically relevant abnormal laboratory values (clinical chemistry and haematology) at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the study results according to Investigator judgement. . - Pregnant or lactating women. |
Country | Name | City | State |
---|---|---|---|
North Macedonia | PHI University Clinic of Pulmonology and Allergology | Skopje | |
Ukraine | Medical Center of Limited Liability Company "Arensia Exploratory Medicine", department of Clinical Trials | Kyiv | |
United Kingdom | Queen Elizabeth Hospital - NIHR Birmingham Clinical Research Facility - University Hospitals Birmingham NHS Foundation Trust | Birmingham | |
United Kingdom | Royal Papworth Hospital NHSFT - Cambridge Biomedical Campus | Cambridge | |
United Kingdom | University of Dundee, NHS Tayside - Ninewells Hospital & Medical School | Dundee | |
United Kingdom | Interstitial Lung Disease Research - NHS Lothian - Royal Infirmary of Edinburgh, | Edinburgh | |
United Kingdom | Liverpool Clinical Research Facility - Liverpool University Hospital Foundation Trust | Liverpool | |
United Kingdom | Medicines Evaluation Unit - The Langley Building | Manchester | |
United Kingdom | University Hospital Southampton - Department of Respiratory Medicine | Southampton |
Lead Sponsor | Collaborator |
---|---|
Chiesi Farmaceutici S.p.A. |
North Macedonia, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Transglutaminase 2 levels in plasma | To evaluate Transglutaminase 2 levels in plasma changes from baseline over time will be described | From predose up to 84 days post dose | |
Primary | Adverse Event recording | Adverse Event recording | From pre-dose up to day 84 | |
Secondary | Systemic exposure (area under the concentration-time curve from zero to time) to CHF10067. | To evaluate the area under the concentration-time curve from zero to the last quantifiable concentration (AUC0-t) of CHF10067 after a single dose. | From pre-dose up to day 84 | |
Secondary | Area under the concentration-time curve from zero to infinity (AUC0-8) of CHF10067 | To evaluate the area under the concentration-time curve from zero to infinity (AUC0-8) of CHF10067 after a single dose | From pre-dose up to day 84 | |
Secondary | Maximum plasma concentration (Cmax) of CHF10067 | To evaluate the Cmax (maximum observed concentration) after a single dose of CHF10067 | From pre-dose up to day 84 | |
Secondary | Time to Cmax | To evaluate the Time to Cmax (tmax) (time to maximum observed concentration) | From pre-dose up to day 84 | |
Secondary | terminal half-life (t1/2) of CHF10067 | To evaluate the Time to t1/2 of CHF10067 | From pre-dose up to day 84 | |
Secondary | Evaluation of CHF10067 immunogenicity profile | Evaluation of Anti Drug Antibodies and neutralising antibody (nAb) | From predose up to 84 days post dose | |
Secondary | Vital signs | Systolic and diastolic blood pressure | From pre-dose up to day 84 | |
Secondary | Oxygen saturation | Oxygen saturation measured via pulse oximetry | From pre-dose up to day 84 | |
Secondary | 12-lead ECG (Electrocardiogram) - HR | The Heart Rate will be summarised using descriptive statistics at each analysis time point by treatment. | From pre-dose up to day 84 | |
Secondary | 12-lead ECG (Electrocardiogram)-PR interval | PR interval will be summarised using descriptive statistics at each analysis time point by treatment. | From pre-dose up to day 84 | |
Secondary | 12-lead ECG (Electrocardiogram) - QRS interval | QRS Interval will be summarised using descriptive statistics at each analysis time point by treatment. | From pre-dose up to day 84 | |
Secondary | 12-lead ECG (Electrocardiogram) QTCF | the number and percentage of subjects with abnormal actual QTCF (QT corrected for heart rate by Fridericia's formula) | From pre-dose up to day 84 | |
Secondary | Spirometry FEV1 | FEV1 (forced expiratory volume in the first second) parameters will be summarised using descriptive statistics at each analysis time point by treatment. | From pre-dose up to day 84 | |
Secondary | Spirometry FVC | FVC (forced vital capacity) parameters will be summarised using descriptive statistics at each analysis time point by treatment. | From pre-dose up to day 84 | |
Secondary | Diffusing capacity (DLCO) | Diffusing capacity (DLCO) parameters will be summarised using descriptive statistics at each analysis time point by treatment. | From pre-dose up to day 84 | |
Secondary | Body temperature | Body temperature will be monitored | at screening, pre-dose, every 15 minutes during the infusion (e.g., 15, 30, 45, 60, 75, 90, 105, etc.), at the end of the infusion and 30 min, 1, 2, 3, 4, 6, 8, and 20 hours after the end of the infusion and 5, 7, 14, 28, 56, and 84 days post-dose | |
Secondary | Pulse rate | Pulse rate will be monitored | At screening, pre-dose, every 15 minutes during the infusion (e.g., 15, 30, 45, 60, 75, 90, 105, etc.), at the end of the infusion and 30 min, 1, 2, 3, 4, 6, 8, and 20 hours after the end of the infusion and 5, 7, 14, 28, 56, and 84 days post-dose | |
Secondary | Respiratory rate | Respiratory rate will be monitored | At screening, pre-dose, every 15 minutes during the infusion (e.g., 15, 30, 45, 60, 75, 90, 105, etc.), at the end of the infusion and 30 min, 1, 2, 3, 4, 6, 8, and 20 hours after the end of the infusion and 5, 7, 14, 28, 56, and 84 days post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Not yet recruiting |
NCT06241560 -
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
|
Phase 2 | |
Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
Not yet recruiting |
NCT06422884 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
|
Phase 2 | |
Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 |